China Preliminarily Sets Principles For The Next Round Drug Price Cuts
This article was originally published in PharmAsia News
Executive Summary
Sources disclosed that China’s next round of mandatory drug price reductions will mainly affect cancer, cardiovascular, and infectious disease therapies and will lower the prices of general medicines by 15% on average, off-patent drugs by 10%, and patented drugs by 7%.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 26 March
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 26 March
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
FDA Delivers OTC Monograph Facility Fees For Fiscal 2024 With Highlights On Some RSVPs
FDA “is highlighting” in its FY2024 facility fees announcement, and using italics for “emphasis added” for some statements, that businesses previously but no longer making hand sanitizers, though still selling the products, should contact the agency to assure they’re not assessed fees.